Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.
about
Concomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases.Mechanisms of tumor cell resistance to the current targeted-therapy agents.Disease flare after discontinuing gefitinib in a patient with lung adenocarcinoma and concomitant epithelial growth factor receptor mutation and anaplastic lymphoma kinase translocationResponses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation.Q58714451
P2860
Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Poor response to gefitinib in ...... lymphoma kinase rearrangement.
@ast
Poor response to gefitinib in ...... lymphoma kinase rearrangement.
@en
type
label
Poor response to gefitinib in ...... lymphoma kinase rearrangement.
@ast
Poor response to gefitinib in ...... lymphoma kinase rearrangement.
@en
prefLabel
Poor response to gefitinib in ...... lymphoma kinase rearrangement.
@ast
Poor response to gefitinib in ...... lymphoma kinase rearrangement.
@en
P2093
P2860
P356
P1433
P1476
Poor response to gefitinib in ...... lymphoma kinase rearrangement.
@en
P2093
Jianya Zhou
Jianying Zhou
Jing Zheng
Yihong Sheng
P2860
P304
P356
10.1111/1759-7714.12146
P577
2015-03-02T00:00:00Z